Spyre Therapeutics IncSYRE
Price$89.93

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$155.2MTTM through 30 Jun 2026
Free Cash Flow -$208.9MTTM through 30 Jun 2026

Margins

Current

Returns

-14.1%ROE
-13.2%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio18.53x
Net Debt-$741.5Mnet cash position
Cash & Equivalents$162M

Quality Metrics

Altman Z-Score66.78
Piotroski F-Score3 / 9
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $0
Diluted EPS
'20'21'22'23
FY2023: $-49.12

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Drug Discovery and Development$0
View details

The company operates in a single segment focused on developing next-generation monoclonal antibodies for inflammatory bowel disease (IBD) and rheumatic diseases.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.